18f-labeled psma-targeted pet imaging agents
US-2025375542-A1 · Dec 11, 2025 · US
US2025092072A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2025092072-A1 |
| Application number | US-202418773657-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jul 16, 2024 |
| Priority date | Feb 17, 2018 |
| Publication date | Mar 20, 2025 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interference (RNAi) agents.
Opening claim text (preview).
1 - 17 . (canceled) 18 . A compound of Formula II, or a pharmaceutically acceptable salt thereof, wherein, L 1 , L 2 , and L 3 are each independently linkers comprising optionally substituted alkylene; L 4 is a linker comprising optionally substituted alkylene, optionally substituted arylene, and optionally substituted cycloalkylene; each instance of R 1 is optionally substituted alkyl; R 2 is optionally substituted alkyl; and R 4 is H or optionally substituted alkyl. 19 - 24 . (canceled) 25 . A compound of Formula III, or a pharmaceutically acceptable salt thereof, wherein, L 1 , L 2 , and L 3 are each independently linkers comprising optionally substituted alkylene; L 4 is a linker comprising optionally substituted alkylene, optionally substituted arylene, and optionally substituted cycloalkylene; R 4 is H or optionally substituted alkyl; X is O or S; and RNA comprises or consists of an RNAi agent. 26 - 31 . (canceled) 32 . The compound or pharmaceutically acceptable salt thereof of claim 25 , wherein the compound is selected from the group consisting of: Compound No. Structure 1-O-III 1-S-III 2-O-III 2-S-III 3-O-III 3-S-III 4-O-III 4-S-III 5-O-III 5-S-III 6-O-III 6-S-III 7-O-III 7-S-III 8-O-III 8-S-III 9-O-III 9-S-III 10-O-III 10-S-III 11-O-III
the bicyclo ring system containing eight carbon atoms · CPC title
the bicyclo ring system containing five carbon atoms · CPC title
The ring being saturated · CPC title
Optical isomers · CPC title
Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.